Skip to content
Business Times – Lifestyle
Author:
Kenai Therapeutics/BIOCOM
Kenai Therapeutics Announces Completion of Enrollment in Phase 1b/2a REPLACE™ Trial of RNDP-001 in Idiopathic Parkinson’s Disease
July 7, 2026
Kenai Therapeutics Appoints Allen Waldrop to Board of Directors
March 12, 2026